Clinical Trial Update: A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

This document reports an early-phase 1 study of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone for relapsed/refractory multiple myeloma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Iberdomide (CC-220) (Iberdomide)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Multiple Myeloma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING